Dr. Reddy's Laboratories Limited — Important, 06-02-2025: Arrangements for strategic, technical, manufacturing, or marketing tie up

Dr. Reddy’s Laboratories has entered into a licensing agreement with Shanghai Henlius Biotech for the commercialization of the biosimilar 'Daratumumab' (HLX15) in the U.S. and Europe. Under the agreement, Dr. Reddy's Swiss will pay up to $131.6 million, including an upfront payment of $33 million, with Henlius also entitled to royalties based on the annual net sales. This collaboration allows Dr. Reddy’s to leverage Henlius’s development and manufacturing capabilities, enhancing its oncology portfolio. The exclusive rights to commercialize both subcutaneous and intravenous formulations bolster Dr. Reddy's position in a rapidly growing market for biosimilars. This strategic move is expected to contribute positively to future revenue streams and reflects the company's commitment to providing affordable cancer treatments. Investors should view this development as a potential growth opportunity due to the increasing demand for oncology biosimilars in key markets.